Johnson & Johnson Book Value Per Share 2010-2025 | JNJ

Current and historical book value per share for Johnson & Johnson (JNJ) from 2010 to 2025. Book value per share can be defined as the amount of equity available to shareholders expressed on a per common share basis. Johnson & Johnson book value per share for the three months ending March 31, 2025 was $32.47.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $366.710B $88.821B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $734.922B 56.36
AbbVie (ABBV) United States $322.033B 17.75
Novo Nordisk (NVO) Denmark $305.897B 20.27
Roche Holding AG (RHHBY) Switzerland $260.921B 0.00
Novartis AG (NVS) Switzerland $253.512B 14.48
Merck (MRK) United States $198.623B 10.15
Pfizer (PFE) United States $137.529B 7.54
Sanofi (SNY) France $117.350B 11.56
Bayer (BAYRY) Germany $30.927B 6.30
Innoviva (INVA) United States $1.253B 13.13